11 completed, 7 recruiting, 3 active not recruiting, 3 unknown. 29 Phase 1, 8 Phase 2.
Follow Hypopharyngeal Neoplasms: new trials by email Literature Review of Hypopharyngeal Neoplasms trials Research Report on Hypopharyngeal Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Addition of an Anti-Cancer Drug, Camonsertib, to Radiation Therapy for Recurrent Head and Neck Squamous Cell Carcinoma Biospecimen Collection, Camonsertib, Computed Tomography - Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Recurrent Head and Neck Squamous Cell Carcinoma | Phase 1 | Recruiting | National Cancer Institute (NCI) | 39 | 2027-02-13 | 2026-10-29 |
| Ficerafusp Alfa, Pembrolizumab, and Stereotactic Body Radiotherapy (SBRT) for Head and Neck Squamous Cell Carcinoma (HNSCC) Hypofractionated Stereotactic Body Radiotherapy (SBRT), Pembrolizumab, Ficerafusp alfa - Head and Neck Squamous Cell Carcinoma, HPV-Negative Squamous Cell Carcinoma | Phase 1 / Phase 2 | Not yet recruiting | Washington University School of Medicine | 45 | 2026-11-30 | 2026-11-03 |
| Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer SX-682, DTX - Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 120 | 2026-11-11 | 2026-11-06 |
| TMV Vaccine Alone or With Toripalimab-tpzi for Recurrent Head and Neck Squamous Cell Carcinoma TMV Vaccine, Toripalimab-tpzi - Squamous Cell Carcinoma of Head and Neck, Squamous Cell Carcinoma of Head and Neck (SCCHN) | Phase 1 | Recruiting | Metaclipse Therapeutics Corporation | 30 | 2026-10-01 | 2026-10-27 |
| Thermotherapy for Head and Neck Cancer Patients Thermotherapy, Radiotherapy, Concurrent chemoradiation - Head and Neck Cancer, Oropharyngeal Carcinoma | Phase 1 | Recruiting | Erasmus Medical Center | 30 | 2026-09-01 | 2026-09-02 |
| TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer Autologous Tumor Membrane Vesicles Vaccine, Biospecimen Collection, Computed Tomography - Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma | Phase 1 | Recruiting | Emory University | 40 | 2025-05-08 | 2026-03-04 |
| Thermotherapy for Locally Advanced Head and Neck Cancer Thermotherapy, radiotherapy - Head and Neck Cancer, Oropharyngeal Carcinoma | Phase 1 | Active not recruiting | Erasmus Medical Center | 2 | 2025-05-01 | 2026-09-02 |
| A Study of Concurrent Chemoradiation in Combination With or Without PD1 Inhibitor AB122 Adenosine 2a Receptor / Adenosine 2b Receptor Inhibitor AB928 Therapies in Locally Advanced Head and Neck Cancers Zimberelimab, Etrumadenant, Cisplatin - Head and Neck Cancer, Squamous Cell Carcinoma of Head and Neck | Phase 1 | Withdrawn | Jennifer Choe | 2023-12-31 | 2023-11-30 | |
| Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer Biopsy Procedure, Biospecimen Collection, Cisplatin - Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Phase 1 | Recruiting | National Cancer Institute (NCI) | 46 | 2022-09-19 | 2026-09-22 |
| Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck Cancer Biospecimen Collection, Computed Tomography, Elimusertib - Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 7 | 2022-07-06 | 2026-08-21 |
| Testing the Addition of M3814 (Peposertib) to Radiation Therapy for Patients With Advanced Head and Neck Cancer Who Cannot Take Cisplatin Intensity-Modulated Radiation Therapy, Peposertib - Advanced Head and Neck Squamous Cell Carcinoma, Advanced Hypopharyngeal Squamous Cell Carcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 21 | 2021-12-20 | 2026-10-13 |
| Image-guided Proton Therapy for the Treatment of Locally Advanced Unresectable Head and Neck Cancer Proton Beam Radiation Therapy, Quality-of-Life Assessment, Questionnaire Administration - Locally Advanced Head and Neck Squamous Cell Carcinoma, Locally Advanced Hypopharyngeal Squamous Cell Carcinoma | Phase 1 | Completed | M.D. Anderson Cancer Center | 3 | 2020-10-19 | 2024-10-29 |
| Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) INBRX-106 - Hexavalent OX40 agonist antibody, pembrolizumab 200 mg, pembrolizumab 400 mg - Solid Tumor, Non-Small Cell Lung Cancer | Phase 1 / Phase 2 | Recruiting | Inhibrx Biosciences, Inc | 340 | 2019-12-10 | 2026-11-06 |
| Pembrolizumab in Combination With CRT for LA-SCCHN pembrolizumab (MK-3475), Cisplatin, Radiation - Head and Neck Cancer, Squamous Cell Carcinoma | Phase 1 | Completed | Sanford Health | 59 | 2015-11-01 | 2025-10-07 |
| Phase Ib Study of BKM120 With Cisplatin and XRT in High Risk Locally Advanced Squamous Cell Cancer of Head and Neck BKM120, Cisplatin, Intensity-modulated radiotherapy (IMRT) - Carcinoma, Squamous Cell of Head and Neck, HPV Positive Oropharyngeal Squamous Cell Carcinoma | Phase 1 | Completed | Dana-Farber Cancer Institute | 23 | 2014-09-29 | 2026-11-05 |
| 18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy 18F-fludeoxyglucose (18F-FDG), 18F-FPPRGD2 - Adult Giant Cell Glioblastoma, Adult Glioblastoma | Phase 1 / Phase 2 | Completed | Sanjiv Sam Gambhir | 25 | 2013-03-04 | 2019-10-03 |
| Photodynamic Therapy in Treating Patients With Premalignant or Early Stage Head and Neck Tumors aminolevulinic acid hydrochloride - Head and Neck Cancer, Precancerous Condition | Phase 1 | Completed | Abramson Cancer Center at Penn Medicine | 35 | 2009-01-01 | 2019-04-23 |
| Phase 1b Food Based Modulation of Biomarkers in Human Tissues at High-Risk for Oral Cancer. placebo, laboratory biomarker analysis, questionnaire administration - Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Salivary Gland Squamous Cell Carcinoma | Phase 1 / Phase 2 | Completed | Ohio State University Comprehensive Cancer Center | 70 | 2007-09-04 | 2020-02-20 |
| Pemetrexed Disodium and Docetaxel in Treating Patients With Advanced Solid Tumors Taxotere (Docetaxel), Alimta (Pemetrexed) - Breast Cancer, Esophageal Cancer | Phase 1 | Completed | University of Arizona | 33 | 2005-09-01 | 2015-12-03 |
| Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer doxorubicin hydrochloride, motexafin gadolinium - Breast Cancer, Chronic Myeloproliferative Disorders | Phase 1 | Completed | University of Wisconsin, Madison | 2002-02-01 | 2019-12-17 |
Showing 20 of 29. Sign in to see all of them.
Laryngeal Neoplasms (26) · Oropharyngeal Neoplasms (23) · Mouth Neoplasms (22) · Head and Neck Neoplasms (19) · Squamous Cell Carcinoma of Head and Neck (17) · Nasopharyngeal Neoplasms (11) · Salivary Gland Neoplasms (9) · Carcinoma (8) · Breast Neoplasms (4) · Carcinoma, Non-Small-Cell Lung (4) · Prostatic Neoplasms (4) · Carcinoma, Squamous Cell (3) · Esthesioneuroblastoma, Olfactory (3) · Lung Neoplasms (3)
Otorhinolaryngologic Diseases (29) · Otorhinolaryngologic Neoplasms (29) · Pharyngeal Diseases (29) · Stomatognathic Diseases (29) · Neoplasms by Site (28) · Pharyngeal Neoplasms (28) · Neoplasms (27) · Respiratory Tract Diseases (27) · Respiratory Tract Neoplasms (27) · Laryngeal Diseases (25) · Mouth Diseases (25) · Neoplasms by Histologic Type (24) · Neoplasms, Glandular and Epithelial (23) · Carcinoma (16) · Carcinoma, Squamous Cell (15)
Cisplatin (8) · Radiotherapy (6) · pembrolizumab (5) · Magnetic Resonance Spectroscopy (4) · Paclitaxel (4) · Specimen Handling (4) · Fluorouracil (3) · Gemcitabine (3) · Radiation (3) · Biopsy (2) · Diathermy (2) · Hyperthermia, Induced (2) · Pemetrexed (2) · Radiosurgery (2) · Radiotherapy, Intensity-Modulated (2)
National Cancer Institute (NCI) (7) · Erasmus Medical Center (2) · Abramson Cancer Center at Penn Medicine (1) · Case Comprehensive Cancer Center (1) · Dana-Farber Cancer Institute (1) · Emory University (1) · Hope Cancer Institute, Inc. (1) · Inhibrx Biosciences, Inc (1) · Jennifer Choe (1) · M.D. Anderson Cancer Center (1) · Memorial Sloan Kettering Cancer Center (1) · Metaclipse Therapeutics Corporation (1) · Ohio State University Comprehensive Cancer Center (1) · Pharmacyclics LLC. (1) · Robert H. Lurie Cancer Center (1)
United States (25) · Canada (2) · Netherlands (2) · Singapore (1) · South Korea (1) · Taiwan (1)
Michiel Kroesen, MD, Dr. (2) · Yvonne M Mowery (2) · Amit Agrawal (1) · Anthony Fyles, MD (1) · Athanassios Argiris, MD (1) · Charalampos Floudas, M.D. (1) · Christopher Pack, PhD (1) · Clifton D Fuller (1) · David R. Spriggs, MD (1) · Dong M. Shin, MD, FACP, FAAAS (1) · Everett E. Vokes, MD (1) · Fred R. Rosen, MD (1) · Jennifer Choe, MD, PhD (1) · Kristen Jacobsen, PhD (1)
PMID 25965900, PMID 26062933, PMID 26611425, PMID 30850872, PMID 32479189, PMID 33004905, PMID 34841093, PMID 40404202
UM1CA186690 (2), P30CA014520 (1), P30CA023074 (1), P30CA043703 (1), P30CA138292 (1), R01CA262123 (1), U01CA062502 (1), U10CA180868 (1), UM1CA186644 (1)